title: Molecular staging of non-small cell lung cancer according to K-ras genotypes.
abstract: We have previously demonstrated a strong association between K-ras gene mutations, as determined by PCR followed by allele-specific oligonucleotide hybridization (ASO-h), and survival in non-small cell lung cancer patients. The purpose of this study was to determine the relationship between tumor aggressiveness and specific-type K-ras point mutations in non-small cell lung cancer. We developed procedures to examine the status of the K-ras gene by ASO-h and by single-strand conformation polymorphism assay of DNA obtained from formalin-fixed paraffin-embedded tumors. K-ras point mutations at codons 12 and 61 were assessed in 275 consecutively treated stage I-IV non-small cell lung cancers. Among patients with stage I disease, median survival time was 41.5 months in those whose tumors had no evidence of K-ras mutations and 27 months in those with K-ras 12 mutations; among patients with stage IIIA disease, median survival time was 7 months in those with K-ras codon 12 aspartic and serine mutations and 15 months for those with other K-ras mutations (P = 0.01). In a multivariate analysis, specific-type K-ras codon 12 point mutation remained a strong predictive factor (hazard ratio for death, 2.06; 95% confidence interval, 1.11-3.81; P = 0.02) after adjustment for other evaluated factors, including TNM stage and histology. Thus, we concluded that in patients with non-small cell lung cancer, specific K-ras 12 point mutations detected by DNA amplification and either ASO-h or single-strand conformation polymorphism methods predicted a significantly increased risk of recurrence and death, independently of stage and histology.
authors.affiliation: Medical Oncology Service, Laboratory of Molecular Biology of Cancer, Department of Pathology, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Rosell
authors.forename: M
authors.initials: M
authors.lastname: Monzó
authors.forename: A
authors.initials: A
authors.lastname: Pifarré
authors.forename: A
authors.initials: A
authors.lastname: Ariza
authors.forename: J J
authors.initials: JJ
authors.lastname: Sánchez
authors.forename: I
authors.initials: I
authors.lastname: Moreno
authors.forename: J
authors.initials: J
authors.lastname: Maurel
authors.forename: M P
authors.initials: MP
authors.lastname: López
authors.forename: A
authors.initials: A
authors.lastname: Abad
authors.forename: J M
authors.initials: JM
authors.lastname: de Anta
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality; D005260:Female; D016158:Genes, p53; D011905:Genes, ras; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation